# Endeavor BioMedicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endeavor-biomedicines

- Industry: Biotechnology
- Headquarters: Solana Beach, US
- Website: www.endeavorbiomedicines.com
- Total disclosed funding: $284M
- Latest round: Series C (Apr 22, 2024)
- Investors on record: 17

## About

Based in California, US, and founded in 2018 by CEO John Hood, and CSO Miguel de los Rios, Endeavor BioMedicines, Inc., a.k.a. Endeavor BioMedicines operates as a developer of therapies and medicines for patients with life-threatening diseases such as fibrotic lung diseases and cancer. In April 2024, Endeavor BioMedicines, Inc. raised USD 5 million in venture debt funding. The round was part of a larger USD 137.5 million venture debt and Series C funding.

The company’s pipeline includes ENV-101 (IPF), ENV-101 (PPF), and ENV-501 (oncology). Endeavor BioMedicines is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF).

The company plans to use its proceeds from April 2024 funding to advance the clinical development of ENV-101 for fibrotic lung diseases and ENV-501 for HER3-positive solid tumors.

## Funding rounds

- Series C, Apr 22, 2024, $133M — T Rowe Price, Invus [DUP], Tekla Capital Management, Longitude Capital, Fidelity Investments, Omega Funds, Ally Bridge Group, Perceptive Advisors, Avidity Partners, SymBiosis Capital Management, Eckuity Capital, Piper Heartland Healthcare Capital, Woodline Partners, Matrix Capital Management Company, Velosity Capital
- Series B, Jan 21, 2022, $89M — T Rowe Price, Tekla Capital Management, Longitude Capital, Omega Funds, Piper Sandler, Ally Bridge Group, Revelation Partners, Perceptive Advisors, Avidity Partners
- Series A, Jan 7, 2021, $62M — Longitude Capital, Omega Funds

## Investors

- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B, Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B, Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B, Series C
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series B, Series C
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Avidity Partners — Series B, Series C
- Invus [DUP] — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series C
- Eckuity Capital (https://capitalatlas.ai/funds/eckuity-capital) — Series C
- Piper Heartland Healthcare Capital — Series C
- Woodline Partners — Series C
- Matrix Capital Management Company — Series C
- Velosity Capital — Series C